METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC

Documenti analoghi

• Leveraging programmed cell death patterns to predict prognosis and therapeutic sensitivity in OSCC
  di: An Wang, et al.
  Pubblicazione: (2024)
• Characteristics and clinical significance of tertiary lymphoid structures in OSCC
  di: Mianfeng Yao, et al.
  Pubblicazione: (2024)
• The Application of Adjuvant Radiotherapy in pN1 OSCC Patients Without Adverse Pathologic Features
  di: Bo Li, et al.
  Pubblicazione: (2025)
• Histone Lysine Lactylation (Kla)‐induced BCAM Promotes OSCC Progression and Cis‐Platinum Resistance
  di: Guangzhao Huang, et al.
  Pubblicazione: (2024)
• Development and Validation of Machine Learning Models for Predicting Tumor Progression in OSCC
  di: Xueying Mei, et al.
  Pubblicazione: (2024)